UB Paderborn / Katalog / Suche / in CDI

1 – 16 von 16

Sortiert nach

Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody–drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study

The lancet oncology, 2024-03, Vol.25 (3), p.388-399

2024

Link zum Volltext

Verfügbarkeit prüfen

AML treatment: conventional chemotherapy and emerging novel agents

Trends in pharmacological sciences (Regular ed.), 2024-04

2024

Link zum Volltext

Verfügbarkeit prüfen

Novel Therapeutic Targets in Acute Myeloid Leukemia (AML)

Current oncology reports, 2024-04, Vol.26 (4), p.409-420

2024

Link zum Volltext

Verfügbarkeit prüfen

Tagraxofusp, a first-in-class CD123-targeted agent: Five-year postapproval comprehensive review of the literature

Cancer, 2024-04

2024

Link zum Volltext

Verfügbarkeit prüfen

Diagnosing and Treating Blastic Plasmacytoid Dendritic Cell Neoplasm in a Resource-Limited Setting

Oncology (Williston Park, N.Y.), 2024-03, Vol.38 (3), p.104-106

2024

Link zum Volltext

Verfügbarkeit prüfen

Single-cell systems pharmacology identifies development-driven drug response and combination therapy in B cell acute lymphoblastic leukemia

Cancer cell, 2024-04, Vol.42 (4), p.552-567.e6

2024

Link zum Volltext

Verfügbarkeit prüfen

Characteristics and outcomes of patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia after failure of a frontline ponatinib-containing therapy

American journal of hematology, 2024-04

2024

Link zum Volltext

Verfügbarkeit prüfen

Targeting the CXCL12/CXCR4 axis in acute myeloid leukemia: from bench to bedside

The Korean journal of internal medicine, 2017-03, p.248-257

2017

Link zum Volltext

Verfügbarkeit prüfen

Improving Allogenic Hematopoietic Stem Cell Transplantation Equity: Assessing Mismatched Donor Opportunities with Real World Data in a Minority-Rich Cohort

Transplantation and cellular therapy, 2024-02, Vol.30 (2), p.S320-S320

2024

Link zum Volltext

Verfügbarkeit prüfen

Acute myeloid leukemia with mast cell differentiation is characterized by interstitial mast cells, complex karyotype, TP53 alterations and poor prognosis

Haematologica (Roma), 2024-03

2024

Link zum Volltext

Verfügbarkeit prüfen

Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study

The Lancet. Haematology, 2024-04, Vol.11 (4), p.e276-e286

2024

Link zum Volltext

Verfügbarkeit prüfen

Feasible diet and circadian interventions reduce in vivo progression of FLT3‐ITD‐positive acute myeloid leukemia

Cancer medicine (Malden, MA), 2024-01, Vol.13 (2), p.e6949-n/a

2024

Link zum Volltext

Verfügbarkeit prüfen

Improving Unrelated Donor Equity: Assessing Mismatched Donor Opportunities with Real-World Data in a Minority-Predominant Cohort

Transplantation and cellular therapy, 2024-02

2024

Link zum Volltext

Verfügbarkeit prüfen

1 – 16 von 16

Suche als RSS-Feed

Aktive Filter

Neu hinzugefügt... seit 90 Tagen

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(16)
Mit Volltextzugriff
(16)

Publikationsform

Artikel
(16)

Sprache

Englisch
(15)
Koreanisch
(1)

Erscheinungsjahr

n.n

Thema

Humans
(8)
Science & Technology
(6)
Acute Myeloid Leukemia
(4)
Leukemia
(4)
Leukemia, Myeloid, Acute - Drug Therapy
(4)
Life Sciences & Biomedicine
(4)
Patients
(4)
Hematology
(3)
Male
(3)
Oncology
(3)
Aged
(2)
Antibodies
(2)
Bone Marrow
(2)
Chemotherapy
(2)
Dendritic Cells
(2)
Female
(2)
Leukemia, Myeloid, Acute - Diagnosis
(2)
Leukemia, Myeloid, Acute - Genetics
(2)
Multidisciplinary Sciences
(2)
Mutation
(2)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 30 Tagen
(6)

Menü

Weitere Dienste

Einstellungen

Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody–drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study

AML treatment: conventional chemotherapy and emerging novel agents

Novel Therapeutic Targets in Acute Myeloid Leukemia (AML)

Tagraxofusp, a first-in-class CD123-targeted agent: Five-year postapproval comprehensive review of the literature

Diagnosing and Treating Blastic Plasmacytoid Dendritic Cell Neoplasm in a Resource-Limited Setting

Single-cell systems pharmacology identifies development-driven drug response and combination therapy in B cell acute lymphoblastic leukemia

Characteristics and outcomes of patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia after failure of a frontline ponatinib-containing therapy

Targeting the CXCL12/CXCR4 axis in acute myeloid leukemia: from bench to bedside

Targeting DNA2 overcomes metabolic reprogramming in multiple myeloma

Improving Allogenic Hematopoietic Stem Cell Transplantation Equity: Assessing Mismatched Donor Opportunities with Real World Data in a Minority-Rich Cohort

Comprehensive characterization of IFNγ signaling in acute myeloid leukemia reveals prognostic and therapeutic strategies

Molecular responses in decitabine- and decitabine/venetoclax-treated patients with acute myeloid leukemia and myelodysplastic syndromes

Acute myeloid leukemia with mast cell differentiation is characterized by interstitial mast cells, complex karyotype, TP53 alterations and poor prognosis

Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study

Feasible diet and circadian interventions reduce in vivo progression of FLT3‐ITD‐positive acute myeloid leukemia

Improving Unrelated Donor Equity: Assessing Mismatched Donor Opportunities with Real-World Data in a Minority-Predominant Cohort

Aktive Filter

Suchergebnisse filtern